trending Market Intelligence /marketintelligence/en/news-insights/trending/FLeH0-w8o2IVjLjEvBGm9Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Acceleron prices common stock offering to raise $230M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Acceleron prices common stock offering to raise $230M

Acceleron Pharma Inc. priced an underwritten public offering of its common shares at $43 apiece.

The Cambridge, Mass.-based biopharmaceutical company will sell 5,348,838 common shares to raise $230 million in gross proceeds. It has also granted the underwriters an option to buy up to an additional 802,325 shares.

Acceleron, which develops therapeutics to treat serious and rare diseases, expects to receive about $215.8 million in net proceeds, which will fund the development of its drug candidates and future development programs. The funds will also be used for general and administrative expenses, as well as capital expenditures, working capital and other general corporate purposes.

The offering is expected to close Jan. 18.

Citigroup, J.P. Morgan and SVB Leerink are acting as joint book-running managers for the offering, with UBS Investment Bank as lead manager.